A personalized approach in the dosing of subcutaneous tocilizumab (TCZ) injections according to body weight appears to be effective in improving outcomes of clinical disease activity in patients with rheumatoid arthritis (RA), suggests a study.
Denosumab appears to have a neutral effect on the risk of composite and specific cardiovascular outcomes among patients with primary osteoporosis, whereas romosozumab may contribute to an increased risk of four-point major adverse cardiovascular event, according to the results of a meta-analysis.
New drug applications approved by US FDA as of 16 - 30 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Both the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) are reliable methods of determining disease activity in Singaporeans with axial spondyloarthritis (axSpA), according to a recent study.
The initiation of immune checkpoint inhibitors for cancer in patients with pre-existing autoimmune disease appears to frequently lead to flares or immune-related adverse effects that are mostly manageable, as shown in a study.
The anti-inflammatory drug colchicine at a dose of 0.5 mg/day significantly reduced the risk of ischaemic cardiovascular (CV) events in individuals with a recent myocardial infarction (MI), according to results of the COLCOT* trial presented at AHA 2019.
Women with rheumatoid arthritis (RA) appear to have low utilization of medications safe to take during pregnancy, commonly discontinuing their medications in the first trimester, a recent study has found.
Men who undergo flexible cystoscopy, particularly with a longer dwell time, may benefit from intraurethral lidocaine as it provides significant pain reduction, suggest the results of a meta-analysis. Evidence is lacking for other tested interventions.